Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1239

Shown on this page

Current sort

Live official records

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more

Conditions: Convulsion, Non-Epileptic
Interventions: ReACT; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Functional Neurological Disorder, Convulsion, Non-Epileptic, Functional Seizure
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 8 Years to 89 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions: Magnetic Resonance Imaging, Prophylactic Cranial Irradiation; Procedure · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 428
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: Conventional Smell Training Group, Scented Marker Group; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Concussion, Mild, Photophobia, Contact Lens
Interventions: Narrow band (tinted) contact lenses, broad band (clear) contact lenses; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Rett Syndrome
Interventions: NGN-401; Genetic
Lead sponsor: Neurogene Inc.; Industry
Eligibility: 3 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Birmingham, Alabama • Oakland, California • Aurora, Colorado + 10 more

Conditions: Orthopedic Disorder, Anterior Cruciate Ligament Injuries
Interventions: Quad tendon, BTB; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Meibomian Gland Dysfunction (MGD)
Interventions: Vevye(Cyclosporine 0.1% Ophthalmic Solution); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Post-prandial Glucose Response
Interventions: Mix of five herbs and spices, Potato entree; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Kidney Stone
Interventions: Low Oxalate Diet, Carbon-13 Ascorbic Acid Oral Load; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1201
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more

About this University of Alabama at Birmingham institution page

What this page lists: ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Alabama at Birmingham

Filter and sort this campus

Live official records

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Retraining and Control Therapy (ReACT)- Adults

Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Boosting Olfactory and Sensory Training Study (BOOST)

Use of Tinted Contact Lenses for Concussion-Related Light Sensitivity

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

Quadriceps Tendon Versus Bone Patellar Tendon Bone Autograft ACL Reconstruction RCT

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

Pilot Assessment of Continuous Glucose Monitor for Post-meal Glucose Responses to Herbs and Spices.

Oxalate Formation From Ascorbic Acid

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

About this University of Alabama at Birmingham institution page